Compensated Cirrhosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for compensated cirrhosis. 36 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
36
Active US patents
40/100
Avg vulnerability
—
Annual revenue covered

Originators in Compensated Cirrhosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 36 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating compensated cirrhosis. Each bar = one year. Y-axis scaled to peak year (10 patents).

10
30
2
31
8
32
6
34
8
35
2
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mavyret
GLECAPREVIR
 AbbVie 36 40 — 2030-06-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11484534 Mavyret method of use 53 2034-03-14
10028937 Mavyret method of use 51 2030-06-10
10028937 Mavyret method of use 51 2030-06-10
10039754 Mavyret method of use 51 2030-06-10
10039754 Mavyret method of use 51 2030-06-10
9586978 Mavyret method of use 51 2030-11-06
9586978 Mavyret method of use 51 2030-11-06
10028937 Mavyret other 51 2030-12-10
10039754 Mavyret other 51 2030-12-10
10028937 Mavyret other 51 2030-12-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9321807 Mavyret composition of matter 0 2035-06-05
9321807 Mavyret composition of matter 0 2035-06-05
RE48923 Mavyret composition of matter 0 2035-05-08
RE48923 Mavyret composition of matter 0 2035-05-08
8937150 Mavyret composition of matter 0 2032-05-18
8937150 Mavyret composition of matter 0 2032-05-18
11246866 Mavyret formulation 33 2036-06-24
11246866 Mavyret other 45 2036-12-24
9321807 Mavyret other 45 2035-12-05
9321807 Mavyret other 45 2035-12-05

Related